Forkhead transcription factor FoxO1 inhibits insulin- and transforming growth factor-β-stimulated plasminogen activator inhibitor-1 expression

Biochemical and Biophysical Research Communications

Volumn 386, Issue 4, 2009, Pages 757-761

  Jung, Yun A ^a   Lee, Kyeong Min ^b   Kim, Mi Kyung ^a   Jung, Gwon Soo ^a   Seo, Ye Jin ^a   Kim, Hye Soon ^a   Cho, Ho Chan ^a   Lee, Ki Up ^c   Park, Keun Gyu ^a   Lee, In Kyu ^b  

^a Keimyung University School of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Forkhead box containing protein FoxO1; Hyperinsulinemia; Liver fibrosis; Plasminogen activator inhibitor 1; Transforming growth factor

Indexed keywords

INSULIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD3 PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; INSULIN TREATMENT; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION;

CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; HYPERINSULINISM; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 67650433374     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.124     Document Type: Article

References (32)

1. Dimova E.Y., and Kietzmann T. The MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2. Ann. NY Acad. Sci. 1090 (2006) 355-367
2. Fogari R., Zoppi A., Preti P., Fogari E., Malamani G., and Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am. J. Hypertens. 14 (2001) 921-926
3. Wahba I.M., and Mak R.H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2 (2007) 550-562
4. Ban C.R., and Twigg S.M. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc. Health Risk Manag. 4 (2008) 575-596
5. Nagamine Y. Transcriptional regulation of the plasminogen activator inhibitor type 1-with an emphasis on negative regulation. Thromb. Haemost. 100 (2008) 1007-1013
6. Yoshida K., Matsuzaki K., Mori S., Tahashi Y., Yamagata H., Furukawa F., Seki T., Nishizawa M., Fujisawa J., and Okazaki K. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am. J. Pathol. 166 (2005) 1029-1039
7. Harte A.L., McTernan P.G., McTernan C.L., Smith S.A., Barnett A.H., and Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes. Metab. 5 (2003) 302-310
8. Mukai Y., Wang C.Y., Rikitake Y., and Liao J.K. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H1937-H1942
9. Nordt T.K., Sawa H., Fujii S., and Sobel B.E. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91 (1995) 764-770
10. Wu G., Chen Y.G., Ozdamar B., Gyuricza C.A., Chong P.A., Wrana J.L., Massagué J., and Shi Y. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 287 (2000) 92-97
11. Wickert L., Chatain N., Kruschinsky K., and Gressner A.M. Glucocorticoids activate TGF-beta induced PAI-1 and CTGF expression in rat hepatocytes. Comp. Hepatol. 6 (2007) 5
12. Kuo M., Zilberfarb V., Gangneux N., Christeff N., and Issad T. O-GlcNAc modification of FoxO1 increases its transcriptional activity: a role in the glucotoxicity phenomenon?. Biochimie 90 (2008) 679-685
13. Hahn-Windgassen A., Nogueira V., Chen C.C., Skeen J.E., Sonenberg N., and Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 280 (2005) 32081-32089
14. Tang E.D., Nuñez G., Barr F.G., and Guan K.L. Negative regulation of the forkhead transcription factor FKHR by Akt. J. Biol. Chem. 274 (1999) 16741-16746
15. Huang H., and Tindall D.J. Dynamic FoxO transcription factors. J. Cell Sci. 120 (2007) 2479-2487 (Review)
16. Das F., Ghosh-Choudhury N., Venkatesan B., Li X., Mahimainathan L., and Choudhury G.G. Akt kinase targets association of CBP with SMAD3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. J. Cell. Physiol. 214 (2008) 513-527
17. Accili D., and Arden K.C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117 (2004) 421-426
18. Barthel A., Schmoll D., and Unterman T.G. FoxO proteins in insulin action and metabolism. Trends Endocrinol. Metab. 16 (2005) 183-189
19. Greer E.L., and Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24 (2005) 7410-7425
20. Nakae J., Oki M., and Cao Y. The FoxO transcription factors and metabolic regulation. FEBS Lett. 582 (2008) 54-67
21. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
22. Biggs W.H., Meisenhelder J., Hunter T., Cavenee W.K., and Arden K.C. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA 96 (1999) 7421-7426
23. Adachi M., Osawa Y., Uchinami H., Kitamura T., Accili D., and Brenner D.A. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 132 (2007) 1434-1446
24. Kutz S.M., Hordines J., McKeown-Longo P.J., and Higgins P.J. TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J. Cell Sci. 114 (2001) 3905-3914
25. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., and Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF-beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17 (1998) 3091-3100
26. de Larrañaga G., Wingeyer S.P., Graffigna M., Belli S., Bendezú K., Alvarez S., Levalle O., and Fainboim H. Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome. Clin. Appl. Thromb. Hemost. 14 (2008) 319-324
27. Alessi M.C., Juhan-Vague I., Kooistra T., Declerck P.J., and Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb. Haemost. 60 (1988) 491-494
28. Schneider D.J., and Sobel B.E. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc. Natl. Acad. Sci. USA 88 (1991) 9959-9963
29. Schneider D.J., Nordt T.K., and Sobel B.E. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells. Diabetes 41 (1992) 890-895
30. Binder B.R., Christ G., Gruber F., Grubic N., Hufnagl P., Krebs M., Mihaly J., and Prager G.W. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol. Sci. 17 (2002) 56-61
31. ten Dijke P., Miyazono K., and Heldin C.H. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem. Sci. 25 (2000) 64-70
32. Moustakas A., Souchelnytskyi S., and Heldin C.H. Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114 (2001) 4359-4369